{"id":"W4391180278","doi":"10.1016/j.jtho.2024.01.012","title":"Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute on Aging; University of California, Irvine; EMD Serono; Genentech; European Society for Medical Oncology; G1 Therapeutics; Seagen; Relay Therapeutics; University of California, San Francisco; NGM Biopharmaceuticals; Cancer Research Institute; AstraZeneca; Novocure; ViewRay; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; International Association for the Study of Lung Cancer; Mirati Therapeutics; Association of American Medical Colleges; GlaxoSmithKline; Pfizer; American Association for Cancer Research; Amgen; American Society of Clinical Oncology; Eli Lilly and Company; Bristol-Myers Squibb; Hope Foundation; Sociedad Española de Oncología Médica; Society for Immunotherapy of Cancer; LUNGevity Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Conquer Cancer Foundation; Sanofi","keywords":"Durvalumab; Medicine; Osimertinib; Common Terminology Criteria for Adverse Events; Retrospective cohort study; Clinical endpoint; Internal medicine; Oncology; Proportional hazards model; Hazard ratio; Cohort; Adverse effect; Confidence interval; Adenocarcinoma; Cancer; Randomized controlled trial; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001354292,0.0008767365,0.001551494,0.0003344829,0.0005417725,0.00116262,0.0007291406,0.0008754806,0.001838238],"category_scores_gemma":[0.002086347,0.0006655457,0.002124052,0.0007545311,0.0007218661,0.00118383,0.0005003411,0.00170143,0.0004144627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276128,"about_ca_system_score_gemma":0.001169894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003132131,"about_ca_topic_score_gemma":0.003923995,"domain_scores_codex":[0.9988515,0.000287251,0.00009781194,0.0003893565,0.0001115845,0.0002625719],"domain_scores_gemma":[0.9985454,0.0002338076,0.0006107801,0.0001916626,0.00008999725,0.0003284314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3120477,0.004321862,0.6436205,0.0002208879,0.006582391,0.000647675,0.0004314378,0.0008795939,0.005644251,0.0002115281,0.001389124,0.02400307],"study_design_scores_gemma":[0.0230647,0.06753557,0.892723,0.0001246509,0.007339721,0.001514863,0.0009557189,0.002397468,0.001701972,0.0004360418,0.002093576,0.0001126007],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989255,0.0005987835,0.0000603072,0.00003603093,0.00001870728,0.0000267658,0.0002140906,0.000002863136,0.0001169631],"genre_scores_gemma":[0.9988411,0.0003096652,0.00008105022,0.00008249161,0.00004701786,0.00003288156,0.0004111458,0.00000526109,0.0001893503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003132131,"threshold_uncertainty_score":0.009258926,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03540123169618212,"score_gpt":0.4502022867821959,"score_spread":0.4148010550860137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}